Russian President calls for reform of national drugs procurement system

16 July 2018
russia_roubles_rubles_money_big

Russia’s President Vladimir Putin has instructed the national government to consider the possibility of reforming the current system of state purchases of drugs in Russia, according to recent statements of the press-service of the Russian Presidential Administration, reports The Pharma Letter’s local correspondent.

As part of these plans, a single platform for public procurements of drugs will be established.

To date, the Russian government has already started reforming the national system of public procurements in the field of pharmaceuticals. That means, starting from July 1 of this year, state purchases of drugs in Russia are having to use weighted average prices for similar drugs’ categories, while effective from January 1, 2019 the use of reference prices for certain categories of drugs will be introduced.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical